• Explore /
  • Videos & Slides
  • / Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.

Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.

Abstract Video & Slides Poster

Presenter

Stephen Chan

Stephen Lam Chan, MD, FRCP, MRCP

Department of Clinical Oncology, Prince of Wales Hospital, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT03778957

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4122)

DOI

10.1200/JCO.2024.42.16_suppl.4122

Abstract #

4122

Poster Bd #

102

Abstract Disclosures

Similar Videos & Slides

Speaker: Riccardo Lencioni, MD

Speaker: Robin Kate Kelley, MD

Videos & Slides

2023 ASCO Breakthrough

Single-Cell Sequencing

Single-Cell Sequencing

Speaker: Ramanuj DasGupta, PhD

Speaker: Masatoshi Kudo, MD, PhD